Locally advanced cervical cancer
Conditions
Interventions
Sponsors
Beidahuang Industry Group General Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed cervical squamous cell carcinoma/adenocarcinoma/adeno-squamous carcinoma; 2. FIGO 2018 stage: IB3~IVA locally advanced cervical cancer. After evaluation by the attending physician, the preferred treatment is radical external pelvic radiation followed by intracavitary brachytherapy with concurrent weekly cisplatin chemotherapy, with no surgical indication for radical treatment; 3. Age 18~75, female; 4. ECOG performance status 0~2, able to tolerate standard concurrent chemoradiotherapy; 5. No prior cervical tumor-related surgery, neoadjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy; 6. Able to provide sufficient paraffin-embedded pathology slides / fresh tumor biopsy tissue for large-panel NGS testing; 7. Participant has signed written informed consent, is compliant, and can cooperate with follow-up; 8. Basic blood tests, liver and kidney function, and bone marrow function show no absolute contraindications to chemo-radiotherapy.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women; 2. Severe heart, lung, liver, kidney, or blood system diseases that make it impossible to tolerate standard radical chemoradiotherapy; 3. Having another systemic malignancy within 5 years (except for completely treated basal cell carcinoma of the skin); 4. History of pelvic radiotherapy or major pelvic surgery that affects the drafting of radiotherapy target areas and dose implementation; 5. Active autoimmune diseases, HIV infection, severe immunodeficiency, active tuberculosis, or other serious infections; 6. Mental illness or cognitive impairment that makes it impossible to sign informed consent and cooperate with follow-up; 7. Expected survival <3 months; 8. Insufficient pathological sample to complete NGS large panel sequencing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate;Correlation between genomic variation features in large-panel NGS and short-term radiotherapy effectiveness (CR PR rate); | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Countries
China
Contacts
Public ContactXiaoling Li
Beidahuang Industry Group General Hospital
Outcome results
None listed